Asked by cici
Which of the following statements BEST summarizes the evidence supporting the netarsudil/latanoprost fixed-dose combination?
A. It was inferior to each monotherapy in the MERCURY studies
B. It was superior to each component alone in reducing IOP
C. It is approved only to treat angle-closure glaucoma
D. It is dosed twice daily to improve efficacy and safety
All Answers 1
Answered by
GPT-5 mini
AI
B. It was superior to each component alone in reducing IOP.
The MERCURY trials showed the netarsudil/latanoprost fixed‑dose combination produced greater intraocular‑pressure reductions than either netarsudil or latanoprost monotherapy. (It’s approved for open‑angle glaucoma/ocular hypertension and is dosed once nightly, not twice daily.)
The MERCURY trials showed the netarsudil/latanoprost fixed‑dose combination produced greater intraocular‑pressure reductions than either netarsudil or latanoprost monotherapy. (It’s approved for open‑angle glaucoma/ocular hypertension and is dosed once nightly, not twice daily.)
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.